^
Association details:
| Biomarker: | CRLF2 rearrangement |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
Excerpt:
...ruxolitinib yielded only a partial response (lower splenic blast count with no difference in peripheral blast count) in xenograft VI, which does not harbor a JAK mutation but is CRLF2-rearranged.
DOI:
https://dx.doi.org/10.1182%2Fblood-2012-03-415448
